Local Coverage DeterminationOncology

Proposed LCD DL40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — Noridian

LCD-DL40222

Document details

Document type: Local Coverage Determination
Issuing body: MAC Contractor
Document ID: LCD-DL40222
Published: June 5, 2026
Effective date: See source document
MAC region: Noridian

Summary

The proposed LCD could potentially impact billing for non-next generation sequencing targeted molecular panel tests used in cancer predictive testing. This may lead to increased scrutiny and changes i

Impact on billing for targeted molecular panel tests.

Affected specialty

Oncology alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40221&ver=4

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

FDA Approval: TRELSTAR (TRIPTORELIN PAMOATE) — Type 3 - New Dosage Form

Policy FDA-NDA022437 · Oncology

Critical

Trelstar (triptorelin pamoate) is an intramuscular injectable GnRH agonist indicated for advanced prostate cancer, billing under Medicare Part B as a physician-administered drug. As an established inj

View alert

FDA Approval: TRELSTAR (TRIPTORELIN PAMOATE) — Type 3 - New Dosage Form

Policy FDA-NDA021288 · Oncology

Critical

Trelstar (triptorelin pamoate) is an intramuscular injectable approved for a new dosage form under NDA021288, placing it firmly in the Medicare Part B billing pathway as a physician-administered drug.

View alert

FDA Approval: TRELSTAR (TRIPTORELIN PAMOATE) — Type 1 - New Molecular Entity

Policy FDA-NDA020715 · Oncology

Critical

Trelstar (triptorelin pamoate) is an intramuscular injectable indicated for prostate cancer, placing it squarely in the Medicare Part B billing pathway as a physician-administered drug. It is typicall

View alert

FDA Approval: ROMVIMZA (VIMSELTINIB) — Type 1 - New Molecular Entity

Policy FDA-NDA219304 · Oncology

High

Romvimza (vimseltinib) is an oral capsule kinase inhibitor approved via NDA219304, placing it squarely in the Medicare Part D billing pathway as a self-administered outpatient drug. As a new molecular

View alert